Event-Driven Stocks

Cartesian Therapeutics, Inc.

RNACNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 5 warning● 3 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$400,000$38.3M$26.0M$110.8M$85.1M$16.6M
Operating income−$143.4M−$43.9M−$86.4M$14.5M−$4.6M−$56.8M
Net income−$130.3M−$77.4M−$219.7M$35.4M−$25.7M−$68.9M
Total assets$296.4M$435.0M$305.1M$165.9M$159.9M$165.4M
Total liabilities$422.7M$441.8M$444.7M$72.1M$137.4M$183.4M
Equity−$126.2M−$6.8M−$440.2M$93.8M$22.5M−$18.0M
EPS (diluted)$-5.02$-4.49$-49.76$0.10$-0.22$-0.68
Shares out.25.9M161.9M153.3M124.3M112.4M86.4M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−35851.3%
Net margin
−32575.5%
Return on equity
103.2%
Return on assets
−44.0%
Return on capital (ROCE)
−50.9%
Liabilities / assets
142.6%
Debt / equity
—
Book value / share
$-4.87
Revenue growth (YoY)
−99.0%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-10.08distress
Accruals / assets
−19.0%clean
Piotroski F-Score
2/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
29
/ 100
Profitability 20Growth 0Catalyst 33Earnings quality 67Financial strength 25

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 3 severe● 5 warning● 2 good
  • Negative shareholder equity
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Strong return on equity (>15%)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20262.2M11.9+2.2%
Apr 30, 20262.2M12.8-2.0%
Apr 15, 20262.2M14.0+2.0%
Mar 31, 20262.2M14.7+2.4%
Mar 13, 20262.1M4.8-1.4%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)